[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340285-105":59,"doc-detail-340285-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","aptbcis1-an-aptamer-cisplatin-conjugate-is-effective-in-lung-cancer-leptomeningeal-carcinomatosis","AptBCis1, An Aptamer - Cisplatin Conjugate, Is Effective in Lung Cancer Leptomeningeal Carcinomatosis","","Treatment of lung cancer leptomeningeal carcinomatosis (LM) remains challenging because the blood-brain barrier (BBB) limits effective drug delivery and cisplatin causes neurotoxicity with limited LM efficacy. AptBCis1 is a cisplatin-conjugated DNA aptamer designed to penetrate the BBB and target cancer. AptB1 backbone was selected by in vivo SELEX using lung cancer LM orthotopic mouse models. AptBCis1 at 1 mg/kg produced stronger tumor suppression than cisplatin 2 mg/kg and reduced cerebrospinal fluid platinum to 10%.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/aptbcis1-an-aptamer-cisplatin-conjugate-is-effective-in-lung-cancer-leptomeningeal-carcinomatosis/340285/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/aptbcis1-an-aptamer-cisplatin-conjugate-is-effective-in-lung-cancer-leptomeningeal-carcinomatosis/340285.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is treating lung cancer leptomeningeal carcinomatosis (LM) difficult?","Question",{"text":112,"@type":113},"Treatment is challenging because the blood-brain barrier restricts effective drug delivery into the CNS, and cisplatin has limited LM effects and neurotoxicity that constrains dosing.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is AptBCis1 and what makes it different from cisplatin?",{"text":117,"@type":113},"AptBCis1 is a cisplatin-conjugated DNA aptamer intended to penetrate the BBB and target cancer. Its backbone, AptB1, was identified by in vivo SELEX using lung cancer LM orthotopic mouse models.",{"name":119,"@type":110,"acceptedAnswer":120},"How did AptBCis1 perform versus cisplatin in the LM mouse models?",{"text":121,"@type":113},"In mice, AptBCis1 at 1 mg/kg (cisplatin-equivalent 0.35 mg/kg) showed superior tumor-suppressive effects compared with cisplatin at 2 mg/kg. Cerebrospinal fluid platinum levels in the AptBCis1 group were 10% of those in the cisplatin group.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340285,1790126894,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","This article is licensed under CC-BY 4.0   \n[www.acsnano.org](www.acsnano.org)  \nAptBCis1, An Aptamer−Cisplatin Conjugate, Is Effective in Lung Cancer Leptomeningeal Carcinomatosis  \nBo-Tsang Huang, Wei-Yun Lai, Chen-Lin Yeh, Yi-Ting Tseng, Konan Peck, Pan-Chyr Yang, and Emily Pei-Ying Lin*  \n Cite This: ACS Nano 2024, 18, 27905−27916  \nRead Online  \n\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n| --- | --- | --- | --- | --- | --- |\n\nABSTRACT: Treatment of lung cancer leptomeningeal carcinomatosis (LM)  \nremains challenging partly due to the biological nature of the blood−brain barrier (BBB). Cisplatin has limited effects on LM, and it is notorious for neurotoxicity. Aptamers are small oligonucleotides considered as antibody surrogates. Here wereport a DNA therapeutics, AptBCis1. AptBCis1 is a cisplatin-conjugated, BBBpenetrating, and cancer-targeting DNA aptamer. Its backbone, AptB1, was identified via in vivo SELEX using lung cancer LM orthotopic mouse models. The AptB1 binds to EAAT2, Nucleolin, and YB-1 proteins. Treatment with AptBCis1 1 mg/kg (equivalent to cisplatin 0.35 mg/kg) showed superior tumor suppressive effects compared to cisplatin 2 mg/kg in mice with lung cancer LM diseases. The cerebrospinal fluid platinum concentration in the AptBCis1 group was 10% of that in the cisplatin group. The data suggested the translational potential of AptBCis1 in lung cancer with LM and in cancers in which platinum-based chemotherapy remains as the standard of care.  \nKEYWORDS: lung cancer, leptomeningeal carcinomatosis, blood−brain barrier, aptamer, cisplatin, in vivo SELEX  \nLeptomeningeal carcinomatosis (LM) was reported in  \n3−10% of patients with advanced-stage lung cancer and  \nwas found in 20% of patients with solid tumors at autopsy.1,2 However, options for treatment are limited, partly due to the existence of the blood−brain barrier (BBB) that restrains effective drug delivery into the central nervous system (CNS). 1−3  \nThe BBB dynamically regulates brain homeostasis. It is composed of brain capillary endothelial cells, pericytes, astrocytic foot processes, and nerve endings terminating on the capillary surface. Tight and adherent junctions between the adjacent endothelial cells prohibit paracellular transport of hydrophilic compounds across the BBB, and transcellular transport by passive diffusion is available only to lipophilic or water-soluble molecules under 500 Da. Moreover, the active efflux transporters on the BBB restrict the entry of chemotherapeutic agents into the CNS.3  \nCisplatin is a platinum compound that constitutes the backbone for lung cancer chemotherapy regimens.4,5 Cisplatin exerts anticancer activity through multiple mechanisms, and the induction of DNA damage response is the most prominent mode of action.6 However, the drug is notorious for neurotoxicity, a side effect that limits its maximum tolerated cumulative dose.7 Moreover, although the systemic response  \nrate of cisplatin achieves up to 21%, it has minimal effects on the LM diseases.1,2,8 This could be due to its inadequate intratumor concentrations. Therefore, precision and effective delivery of the drug are important, especially for cancers with LM.  \nAptamers are small oligonucleotides folded into 3D structures. Aptamers can bind to proteins with high affinity and are considered as antibody surrogates.9 Compared with monoclonal antibodies, aptamers are small and may possess advantages for targeted delivery to certain tissue compartments, for example, the CNS.9, 10 Recent studies showed the potentiality of aptamers in neuro-oncology and neurodegenerative disorders.11, 12 Nevertheless, no aptamer therapeutics for LM diseases have yet been reported.  \nIn the current study, we reported a DNA therapeutics, AptBCis1. AptBCis1 is a cisplatin-conjugated, BBB-penetrat-  \n\n| Received: April 9, 2024\u003Cbr>Revised: September 10, 2024\u003Cbr>Accepted: September 12, 2024\u003Cbr>Published: October 3, 2024 | |\n| --- ","cbCaia9cP89iFFCO","https://ap.wps.com/l/cbCaia9cP89iFFCO","pdf",14680478,12,"English","# Abstract\n# Background and Rationale\n## Blood-Brain Barrier constraints\n## Cisplatin limitations and neurotoxicity\n# Aptamer-based Therapeutic Strategy\n## Aptamer properties and LM knowledge gap\n# Study Approach\n## In vivo SELEX using an LM orthotopic mouse model\n# Results and Discussion\n## LM mouse model establishment","[{\"question\":\"Why is treating lung cancer leptomeningeal carcinomatosis (LM) difficult?\",\"answer\":\"Treatment is challenging because the blood-brain barrier restricts effective drug delivery into the CNS, and cisplatin has limited LM effects and neurotoxicity that constrains dosing.\"},{\"question\":\"What is AptBCis1 and what makes it different from cisplatin?\",\"answer\":\"AptBCis1 is a cisplatin-conjugated DNA aptamer intended to penetrate the BBB and target cancer. Its backbone, AptB1, was identified by in vivo SELEX using lung cancer LM orthotopic mouse models.\"},{\"question\":\"How did AptBCis1 perform versus cisplatin in the LM mouse models?\",\"answer\":\"In mice, AptBCis1 at 1 mg/kg (cisplatin-equivalent 0.35 mg/kg) showed superior tumor-suppressive effects compared with cisplatin at 2 mg/kg. Cerebrospinal fluid platinum levels in the AptBCis1 group were 10% of those in the cisplatin group.\"}]","AptBCis1, An Aptamer - Cisplatin Conjugate, Is Effective in Lung Cancer Leptomeningeal Carcinomatosis | PDF",1790035526,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f12fb803beb7130ee1f8a660596fb86.webp",983,1296,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be9de949c874ae358376092aaa4bd8ac.webp",982,1295,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdd1e0126ba8253d8b49ef5ca571170a.webp",981,1293,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/101d6974e344bf0be05ac255c86bf36e.webp",980,1292]